Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2015-01-31
2017-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Understanding the mechanisms of BAT activation and the role of endocannabinoids in humans is important and beneficial in fighting against the epidemic of obesity and diabetes.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study the investigators use a PET radiotracer \[18F\]FMPEP-d2, which binds to CB1 receptors in vivo, to quantify the CB1 receptor density in BAT, white adipose tissue, muscle and the brain. This study is done once in warm conditions and once during controlled cold exposure. To verify whether the subject has metabolically active BAT, an additional PET scan with the radiotracer \[18F\]FDG is performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
[18F]FMPEP-d2 in warm conditions
PET scan is performed using PET radiotracer \[18F\]FMPEP-d2 in standard room temperature conditions.
[18F]FMPEP-d2
PET radiotracer used in imaging
[18F]FMPEP-d2 in cold conditions
PET scan is performed using PET radiotracer \[18F\]FMPEP-d2 during controlled cold exposure.
Cold exposure
Controlled cold exposure is performed before and during PET scan
[18F]FMPEP-d2
PET radiotracer used in imaging
[18F]FDG in cold conditions
PET scan is performed using PET radiotracer \[18F\]FDG during controlled cold exposure.
Cold exposure
Controlled cold exposure is performed before and during PET scan
[18F]FDG
PET radiotracer used in imaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cold exposure
Controlled cold exposure is performed before and during PET scan
[18F]FMPEP-d2
PET radiotracer used in imaging
[18F]FDG
PET radiotracer used in imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group 1: BMI 20-26 kg/m2, Group2: BMI 27-40 kg/m2
Exclusion Criteria
* Any chronic disease that could affect the study outcome, including medicated type 2 diabetes
* Mental disorder or poor compliance
* Eating disorder or excessive use of alcohol, tobacco smoking or drug use
* Past dose of radiation
* Presence of any ferromagnetic objects that would make MR imaging contraindicated
* Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
18 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pirjo Nuutila
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pirjo Nuutila, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Turku PET Centre (Turku University Hospital)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku PET Centre (Turku University Hospital)
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lahesmaa M, Eriksson O, Gnad T, Oikonen V, Bucci M, Hirvonen J, Koskensalo K, Teuho J, Niemi T, Taittonen M, Lahdenpohja S, U Din M, Haaparanta-Solin M, Pfeifer A, Virtanen KA, Nuutila P. Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue. Diabetes. 2018 Jul;67(7):1226-1236. doi: 10.2337/db17-1366. Epub 2018 Apr 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
42/2014
Identifier Type: -
Identifier Source: org_study_id